Leo Pharma presents positive data in hand eczema phase III trial
Leo Pharma’s chronic hand eczema asset, delgocitinib, has made it across the finish line of a phase III trial called Delta 1.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Leo Pharma reaches endpoints in phase III hand eczema trial
For subscribers